Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling

[1]  D. Krasowska,et al.  Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma , 2016, Postepy dermatologii i alergologii.

[2]  R. Giacomelli,et al.  The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist , 2015, The Journal of Rheumatology.

[3]  R. Giacomelli,et al.  Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts , 2015, Arthritis Research & Therapy.

[4]  T. Makino,et al.  EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin , 2015, The Journal of Immunology.

[5]  Shishira S. Bharadwaj,et al.  Gastrointestinal Manifestations, Malnutrition, and Role of Enteral and Parenteral Nutrition in Patients With Scleroderma , 2015, Journal of clinical gastroenterology.

[6]  S. Hober,et al.  Association of chromosome 19 to lung cancer genotypes and phenotypes , 2015, Cancer and Metastasis Reviews.

[7]  A. Bunck,et al.  Modeling autosomal recessive cutis laxa type 1C in mice reveals distinct functions for Ltbp-4 isoforms , 2015, Disease Models & Mechanisms.

[8]  Xiaodong Zhou,et al.  Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis , 2014, BMC Complementary and Alternative Medicine.

[9]  T. Geiser,et al.  Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis , 2014, Scientific Reports.

[10]  G. Valentini,et al.  Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels , 2014, Journal of Clinical Immunology.

[11]  A. Sterner-Kock,et al.  Latent Transforming Growth Factor β-Binding Protein 4 Is Downregulated in Esophageal Cancer via Promoter Methylation , 2013, PloS one.

[12]  D. Rifkin,et al.  Specificity of latent TGF‐β binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin , 2012, Journal of cellular physiology.

[13]  E. Zabarovsky,et al.  LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. , 2012, Cancer letters.

[14]  Z. Yıldırım,et al.  Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats , 2012, Inflammation.

[15]  D. Rifkin,et al.  LTBPs, more than just an escort service , 2012, Journal of cellular biochemistry.

[16]  S. Law,et al.  The ECM protein LTBP‐2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome , 2011, International journal of cancer.

[17]  F. Arnett,et al.  Attenuation of Expression of Extracellular Matrix Genes with siRNAs to SPARC and CTGF in Skin Fibroblasts of CTGF Transgenic Mice , 2011, International journal of immunopathology and pharmacology.

[18]  A. Sterner-Kock,et al.  Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas , 2011, Cellular Oncology.

[19]  V. Werth,et al.  Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. , 2011, Journal of the American Academy of Dermatology.

[20]  M. Fujimoto,et al.  Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. , 2010, Arthritis and rheumatism.

[21]  J. Keski‐Oja,et al.  Independent regulation of short and long forms of latent TGF‐β binding protein (LTBP)‐4 in cultured fibroblasts and human tissues , 2010, Journal of cellular physiology.

[22]  F. Arnett,et al.  Attenuation of fibrosis in vitro and in vivo with SPARC siRNA , 2010, Arthritis research & therapy.

[23]  M. Jinnin.  Mechanisms of skin fibrosis in systemic sclerosis , 2010, The Journal of dermatology.

[24]  B. Pasche,et al.  Transforming growth factor β as a therapeutic target in systemic sclerosis , 2009, Nature Reviews Rheumatology.

[25]  J. Keski‐Oja,et al.  Fibronectin and heparin binding domains of latent TGF-beta binding protein (LTBP)-4 mediate matrix targeting and cell adhesion. , 2008, Experimental cell research.

[26]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[27]  S. Akira,et al.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. , 2007, The Journal of clinical investigation.

[28]  S. Phan,et al.  Therapies for bleomycin induced lung fibrosis through regulation of TGF‐β1 induced collagen gene expression , 2007, Journal of cellular physiology.

[29]  A. Sterner-Kock,et al.  Latent transforming growth factor binding protein 4 (LTBP‐4) is downregulated in human mammary adenocarcinomas in vitro and in vivo , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  D. Farge,et al.  Transforming growth factor-β signaling through the Smad proteins: Role in systemic sclerosis , 2006 .

[31]  J. Shearstone,et al.  Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. , 2006, Arthritis and rheumatism.

[32]  S. Jabłońska,et al.  An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. , 2004, Arthritis and rheumatism.

[33]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[34]  H. Ihn,et al.  Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. , 1994, Arthritis and rheumatism.

[35]  R. Romiti,et al.  Localized scleroderma: clinical spectrum and therapeutic update* , 2015, Anais brasileiros de dermatologia.

[36]  D. Rifkin,et al.  Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin. , 2009, The American journal of pathology.